Stay updated with breaking news from Transplant Section. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
– First-ever approval of a CRISPR-based gene-editing therapy in the U.S. –– Approximately 16,000 patients 12 years of age and older with severe sickle cell disease may now be eligible for this one-time treatment –– Multiple authorized treatment centers activated –BOSTON & ZUG, Switzerland--(BUSINESS WIRE)--Vertex Ph...
The life-changing drug, developed by Boston-based Vertex and its Swiss partner CRISPR Therapeutics, targets sickle cell disease, an inherited blood disorder that causes crippling pain.
Investegate announcements from NOVARTIS AG CHF0.50(REGD), Novartis five-year Kymriah® data show durable remission and long-term survival maintained in children and young adults with advanced B-cell ALL
In final ELIANA analysis, 55% of patients with relapsed or refractory (r/r) B-cell acute lymphoblastic leukemia (ALL) who were treated with CAR-T cell therapy Kymriah were still alive after five years1 Nearly
/PRNewswire/ -- The behind-the-scenes story detailing the pursuit of a transformative cancer cure will unfold onscreen at the Tribeca Film Festival in New York...